Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
Capital structure increased: Stockholders approved amending the certificate of incorporation to raise authorized common shares from 200 million to 400 million and expanded the 2019 Employee Stock Purchase Plan reserve from to shares. Governance items passed: Ratification of Ernst & Young as independent auditor and an advisory approval of executive compensation were approved, with final voting results to be filed with the SEC. Interested in Altimmune, Inc.? Here are five stocks we like better. MarketBeat Week in Review – 11/4 - 11/8 Altimmune (NASDAQ:ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the company's authorized common stock and employee stock purchase plan share reserve. Meeting format and attendance Jerome Durso, Chairman of the Board, called the meeting to order and said the company was hosting the annual meeting virtually to “be mo
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap [Seeking Alpha]Seeking Alpha
- Altimmune (ALT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Anti-Aging Protein Research Takes a Step Forward with Cell CloningPR Newswire
- Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 4/16/26 - Form 8-K
- 4/6/26 - Form 4
- 4/1/26 - Form 4
- ALT's page on the SEC website